RxDoctor Payments Data

Steven Kong

Physician Assistant · Brooklyn, NYNPI 1407142052

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,745 of the $65,879 with a category attached, or 66.4%. 28 manufacturers reported payments, led by Gilead at 48.2% of the total. Reporting peaked in 2021 at $21,564 and has fallen 50.9% since, to $10,580 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,879in general payments, 2019–2025

Across 809 payments — averaging $81.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$32K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$6K
  • AbbVie$3K
  • AstraZeneca$3K
  • Esperion Therapeutics, Inc.$2K
  • plus $8K from 22 others

What the payments were for

  • Speaking & faculty fees$43,74566%
  • Travel & lodging$1,3542%
  • Food & beverage$20,67931%
  • Gifts$1000%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,879 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl2,539$921,323
NexletolBempedoic Acid1,306$604,367
FarxigaDapagliflozin Propanediol477$275,440
VemlidyTenofovir Alafenamide195$272,851
Breztri AerosphereBudesonide/Glycopyr/Formoterol388$245,793
XareltoRivaroxaban387$226,849
JanuviaSitagliptin Phosphate381$223,206
Evenity (2 Syringes)Romosozumab-Aqqg88$207,593
JardianceEmpagliflozin327$201,225
ProliaDenosumab115$194,146
RybelsusSemaglutide154$152,457
CreonLipase/Protease/Amylase152$139,661
TrulancePlecanatide232$128,938
Diclofenac Epolamine172$112,973
Dexlansoprazole DrDexlansoprazole587$101,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexletol$2,398$604,3671,306 claims
AstraZenecaFarxiga, Breztri Aerosphere, Nexium$2,620$549,749971 claims
AmgenEvenity (2 Syringes), Prolia$1,330$401,739203 claims
MerckJanuvia, Janumet$32$288,184496 claims
AbbVieCreon, Restasis, Linzess$2,696$279,694378 claims
GileadVemlidy$31,763$272,851195 claims
Boehringer IngelheimJardiance, Tradjenta$197$237,713400 claims
Johnson & JohnsonXarelto$604$226,849387 claims
Novo NordiskRybelsus, Ozempic$276$208,228213 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Xifaxan$1,842$155,233244 claims
PfizerEliquis, Nurtec Odt$826$100,820129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →